Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Sees Large Growth in Short Interest

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 32,362 shares, an increase of 1,083.3% from the May 14th total of 2,735 shares. Currently, 5.9% of the company’s stock are short sold. Based on an average daily volume of 54,195 shares, the days-to-cover ratio is presently 0.6 days.

Sigyn Therapeutics Price Performance

OTCMKTS SIGY remained flat at $0.04 during trading on Tuesday. 3,000 shares of the company’s stock were exchanged, compared to its average volume of 30,737. The company has a market capitalization of $100,330.00, a PE ratio of -0.01 and a beta of -0.06. The stock has a fifty day simple moving average of $0.04 and a 200-day simple moving average of $0.62. Sigyn Therapeutics has a 1 year low of $0.01 and a 1 year high of $5.00.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.